Thyroid hormone and blood pressure regulation

Dernellis J, Panaretou M: Effects of thyroid replacement therapy on arterial blood pressure in patients with hypertension and hypothyroidism. Am Heart J 2002, 143:718–724.

Klein I, Ojamaa K: Thyroid hormone and blood pressure regulation. In Hypertension: Pathophysiology, Diagnosis and Management. Edited by Laragh JH, Brenner BM. New York: Raven Press; 1995:2247–2262.

Fletcher AK, Weetman AP: Hypertension and hypothyroidism. J Hum Hypertens 1998, 12:79–82.

Parry CH: Collections from the unpublished papers of the late Caleb Hilliel Parry. Dis Heart 1825, 2:111–165.

Anderson GW, Mariash CN, Oppenheimer JH: Molecular actions of thyroid hormone. In Werner and Ingbar’s The Thyroid: A Fundamental and Clinical Text, edn 8. Edited by Braverman LE, Utiger RD. Philadelphia: Lippincott, Williams & Wilkins; 2000:174–195.

Klein I, Ojamaa K: Thyroid hormone and the cardiovascular system. N Engl J Med 2001, 344:501–509. An overall discussion of the cardiovascular actions of thyroid hormone with specific emphasis on the diagnosis and treatment of both hypothyroidism and hyperthyroidism.

Levey GS, Klein I: Disorders of the thyroid. In Internal Medicine, edn 5. Edited by Stein JH. St. Louis: Mosby; 1998:1323–1349.

Zhang J, Lazar MA: The mechanism of action of thyroid hormones. Annu Rev Physiol 2000, 62:439–466.

Mintz G, Pizzarello R, Klein I: Enhanced left ventricular diastolic function in hyperthyroidism: noninvasive assessment and response to treatment. J Clin Endocrinol Metab 1991, 73:146–150.

Koss KL, Kranias EG: Phospholamban: a prominent regulator of myocardial contractility. Circ Res 1996, 79:1059–63.

Davis PJ, Davis FB: Nongenomic actions of thyroid hormone on the heart. Thyroid 2002, 12:459–466.

Klein I: Clinical, metabolic, and organ-specific indices of thyroid function. In Endocrinology and Metabolism Clinics, vol 30. Edited by Ross DS. Philadelphia: WB Saunders; 2001:415–427.

Goglia F, Silvestri E, Lanni A: Thyroid hormones and mitochondria. Biosci Rep 2002, 22:17–32.

Wrutniak-Cabello C, Casas F, Cabello G: Thyroid hormone action in mitochondria. J Mol Endocrinol 2001, 26:67–77.

Mutvei A, Husman B, Andersson G, et al.: Thyroid hormone and not growth hormone is the principal regulator of mammalian mitochondrial biogenesis. Acta Endocrinologica 1989, 121:235–228.

Klein I: Thyroid hormone and the cardiovascular system. Am J Med 1990, 88:631–637.

Polikar R, Burger AG, Scherrer U, et al.: The thyroid and the heart. Circulation 1993, 87:1435–1441.

Biondi B, Palmieri EA, Lombardi G, et al.: Effects of thyroid hormone on cardiac function: the relative importance of heart rate, loading conditions, and myocardial contractility in the regulation of cardiac performance in human hyperthyroidism. J Clin Endocrinol Metab 2002, 87:968–974. A review of the changes in hemodynamic loading, both preload and afterload, as it effects the cardiovascular response to thyroid disease.

Graettinger JS, Muenster JJ, Selverstone LA, et al.: A correlation of clinical and hemodynamic studies in patients with hyperthyroidism with and without congestive heart failure. J Clin Invest 1959, 38:1316–1327.

Graettinger JS, Muenster JJ, Checchia CS, et al.: A correlation of clinical and hemodynamic studies in patients with hypothyroidism. J Clin Invest 1957, 37:502–510.

Obuobie K, Smith J, Evans LM, et al.: Increased central arterial stiffness in hypothyroidism. J Clin Endocrinol Metab 2002, 87:4662–4666.

Park KW, Kai HB, Ojamaa K, et al.: The direct vasomotor effect of thyroid hormones on rat skeletal muscle resistance arteries. Anesth Analg 1997, 85:734–738. A study of the mechanisms by which T3 acts as a novel vasodilator.

Giannattasio C, Rivolta MR, Failla M, et al.: Large and medium sized artery abnormalities in untreated and treated hypothyroidism. Eur Heart J 1997, 18:1492–1498.

Napoli R, Biondi B, Guardasole V, et al.: Impact of hyperthyroidism and its correction on vascular reactivity in humans. Circulation 2001, 104:3076–3080.

Toft AD, Boon NA: Thyroid disease and the heart. Heart 2000, 84:455–460.

Villabona C, Sahun M, Roca M, et al.: Blood volumes and renal function in overt and subclinical primary hypothyroidism. Am J Med Sci 1999, 318:277–280.

Buccino RA, Spann JF, Pool PE, et al.: Influence of the thyroid state on the intrinsic contractile properties and energy stores of the myocardium. J Clin Invest 1967, 46:1669–1682.

Amidi M, Leon DF, deGroot J, et al.: Effect of the thyroid state on myocardial contractility and ventricular ejection rate in man. Circulation 1968, 38:229–239.

Ojamaa K, Sabet A, Kenessey A, et al.: Regulation of rat cardiac Kv1.5 gene expression by thyroid hormone is rapid and chamber specific. Endocrinology 1999, 140:3170–3176.

Klein I, Hong C: Effects of thyroid hormone on cardiac size and myosin content of the heterotopically transplanted rat heart. J Clin Invest 1986, 77:1694–1698.

Sugden PH, Clerk A: Cellular mechanisms of cardiac hypertrophy. J Mol Med 1998, 76:725–746.

Coleman PS, Parmacek MS, Lesch M, et al.: Protein synthesis and degradation during regression of thyroxine-induced cardiac hypertrophy. J Mol Cell Cardiol 1989, 21:911–925.

Klein I: Thyroxine-induced cardiac hypertrophy: time course of development and inhibition by propranolol. Endocrinology 1988, 123:203–210.

Biondi B, Palmieri EA, Fazio S, et al.: Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab 2000, 85:4701–4705.

Parle JV, Maisonneuve P, Shepard MC, et al.: Prediction of allcause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 2001, 358:861–865.

Savage DD, Levy D, Dannenberg AL, et al.: Association of echocardiographic left ventricular mass with body size, blood pressure and physical activity (the Framingham Study). Am J Cardiol 1990, 65:371–376.

Levy D, Garrison RJ, Savage DD, et al.: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990, 322:1561–1566.

Ventrella SM, Klein I: Beta-adrenergic receptor blocking drugs in the management of hyperthyroidism. Endocrinologist 1994, 4:391–399.

Ojamaa K, Klein I, Sabet A, et al.: Changes in adenylyl cyclase isoforms as a mechanism for thyroid hormone modulation of cardiac beta-adrenergic receptor responsiveness. Metabolism 2000, 49:275–279.

Hoit BD, Khoury SF, Shao Y, et al.: Effects of thyroid hormone on cardiac b-adrenergic responsiveness in conscious baboons. Circulation 1997, 96:592–598.

Stevenson LW: Beta-blockers for stable heart failure. N Engl J Med 2002, 346:1346–1347.

Rockman HA, Koch WJ, Lefkowitz RJ: Cardiac function in genetically engineered mice with altered adrenergic receptor signaling. Am J Physiol Heart Circ Physiol 1997, 272:H1553-H1559.

Resnick LM, Laragh JH: Plasma renin activity in syndromes of thyroid hormone excess and deficiency. Life Sci 1982, 30:585–588.

Kobori H, Hayashi M, Saruta T: Thyroid hormone stimulates renin gene expression through the thyroid hormone response element. Hypertension 2001, 37:99–104.

Marcisz C, Jonderko G, Kucharz EJ: Influence of short-time application of a low sodium diet on blood pressure in patients with hyperthyroidism or hypothyroidism during therapy. Am J Hypertens 2001, 14:995–1002.

Durocher D, Grepin C, Nemer M: Regulation of gene expression in the endocrine heart. Recent Prog Horm Res 1998, 53:7–23.

Lewicki JA, Protter AA: Physiological studies of the natriuretic peptide family. In Hypertension: Pathophysiology, Diagnosis and Management. Edited by Laragh JH, Brenner BM. New York: Raven Press; 1995:1029–1053.

Argentin S, Drouin J, Nemer M: Thyroid hormone stimulates rat pro-natriodilantin mRNA levels in primary cardiocyte cultures. Biochem Biophys Res Commun 1987, 146:1336–1341.

Ladenson PW, Bloch KD, Seidman JG: Modulation of atrial natriuretic factor by thyroid hormone: messenger ribonucleic acid and peptide levels in hypothyroid, euthyroid, and hyperthyroid rat atria and ventricles. Endocrinology 1988, 123:652–657.

Vesely DL: Atrial natriuretic peptide prohormone gene expression: hormones and diseases that upregulate its expression. IUBMB Life 2002, 53:153–159.

Liang F, Webb P, Marimuthu A, et al.: Triiodothyronine increases brain natriuretic peptide (BNP) gene transcription and amplifies endothelin-dependent bnp gene transcription and hypertrophy in neonatal rat ventricular myocytes. J Biol Chem 2003, 278:15073–15083.

Cesareo R, Tarabuso A, Di Benedetto M, et al.: Plasmatic endothelin-1 levels in hyperthyroid patients before and after antithyroid therapy. Minerva Endocrinol 2000, 25:1–3.

Tilly N, Schneider JG, Leidig-Bruckner G, et al.: Endothelin-1 levels in patients with disorders of the thyroid gland. Exp Clin Endocrinol Diabetes 2003, 111:80–84.

Lam HC, Lee JK, Lai KH, et al.: Plasma endothelin levels are unaltered by thyroid hormone status in humans. J Cardiovasc Pharmacol 2000, 36:S382-S385.

Baumgartner-Parzer SM, Wagner L, Reining G, et al.: Increase by tri-iodothyronine of endothelin-1, fibronectin and von Willebrand factor in cultured endothelial cells. J Endocrinol 1997, 154:231–239.

Imai T, Hirata Y, Iwashina M, et al.: Hormonal regulation of rat adrenomedullin gene in vasculature. Endocrinology 1995, 136:1544–1548.

Isumi Y, Shoji H, Sugo S, et al.: Regulation of adrenomedullin production in rat endothelial cells. Endocrinology 1998, 139:838–846.

Tomoda Y, Kikumoto K, Isumi Y, et al.: Cardiac fibroblasts are major production and target cells of adrenomedullin in the heart in vitro. Cardiovasc Res 2001, 49:721–730.

Taniyama M, Kitamura K, Ban Y, et al.: Elevated plasma adrenomedullin level in hyperthyroidism. Eur J Clin Invest 1996, 26:454–456.

Saito I, Kunihiko I, Saruta T: Hypothyroidism as a cause of hypertension. Hypertension 1983, 5:112–115.

Canaris GJ, Manowitz NR, Mayor G, et al.: The Colorado thyroid disease prevalence study. Arch Intern Med 2000, 160:526–534.

Streeten DHP, Anderson GH Jr, Howland T, et al.: Effects of thyroid function on blood pressure: recognition of hypothyroid hypertension. Hypertension 1988, 11:78–83.

Attarian E: Myxedema and hypertension. NY State J Med 1963, 63:2801–2804.

Endo T, Komiya I, Tsukui T, et al.: Reevaluation of possible high incidence of hypertension in hypothyroid patients. Am Heart J 1979, 98:684–688.

Lerman J, Clark RJ, Means JH: The heart in myxedema: electrocardiograms and roentgen-ray measurements before and after therapy. Ann Intern Med 1933, 6:1251–1271.

Saruta T, Kitajima W, Hayashi M, et al.: Renin and aldosterone in hypothyroidism: relation to excretion of sodium and potassium. Clin Endocrinol 1980, 12:483–489.

Thompson WO, Dickie LFN, Morris AE, et al.: The high incidence of hypertension in toxic goiter and I myxedema. Endocrinology 1931, 15:265–272.

Watanakunakorn C, Hodges RE, Evans TC: Myxedema: a study of 400 cases. Arch Intern Med 1965, 1161:183–190.

Cappola AR, Ladenson PW: Hypothyroidism and atherosclerosis. J Clin Endocrinol Metab 2003, 88:2438–2444.

Christ-Crain M, Meier C, Guglielmetti M, et al.: Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebocontrolled trial. Atherosclerosis 2003, 166:379–386.

Hak AE, Pols HAP, Visser TJ, et al.: Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: The Rotterdam Study. Ann Intern Med 2000, 132:270–278.

Saito I, Saruta T: Hypertension in thyroid disorders. Endocrinol Metab Clin N Am 1994, 23:379–386.

Virtanen VK, Saha HHT, Groundstroem KWE, et al.: Thyroid hormone substitution therapy rapidly enhances left-ventricular diastolic function in hypothyroid patients. Cardiology 2001, 96:59–64.

Klein I, Levey GS: The cardiovascular system in thyrotoxicosis. In Werner & Ingbar’s The Thyroid: A Fundamental and Clinical Text, edn 8. Edited by Braverman LE, Utiger RD. Philadelphia: Lippincott Williams & Wilkins; 2000:596–604.

Sawin CT, Geller A, Wolf PA, et al.: Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994, 331:1249–1252.

Marvisi M, Brianti M, Marani G, et al.: Hyperthyroidism and pulmonary hypertension. Respir Med 2002, 96:215–220.

Curnock AL, Dweik RA, Higgins BH, et al.: High prevalence of hypothyroidism in patients with primary pulmonary hypertension. Am J Med Sci 1999, 318:289–292.

Yanai-Landau H, Amital H, Bar-Dayan Y, et al.: Autoimmune aspects of primary pulmonary hypertension. Pathobiology 1995, 63:71–75.

Thurnheer R, Jenni R, Russi EW, et al.: Hyperthyroidism and pulmonary hypertension. J Intern Med 1997, 242:185–188.

Petkov V, Mosgoeller W, Ziesche R: Vasoactive intestinal peptide as a new drug for treatment of pulmonary hypertension. J Clin Invest 2003, 111:1339–1346.

Henning RJ, Sawmiller DR: Vasoactive intestinal peptide: cardiovascular effects. Cardiovasc Res 2001, 27–37.